Agrimetis announces publication of Spinosyn analog patent applications

AgriMetis, LLC recently announced that the first international patent applications covering its insecticide portfolio of novel spinosyns have published.

AgriMetis has validated its ability to discover and develop new innovative agricultural chemical molecules by applying a biopharmaceutical research model. "The novel compounds described in these first published applications show improved efficacy compared to previously known spinosyn analogs. AgriMetis' combination of biology and chemistry has allowed it to develop differentiated compounds in a well studied chemical space," said Brian Green, AgriMetis' VP of Research and Development.

With its recent Series B Preferred Stock financing, AgriMetis is positioned to deliver commercially viable products to the agricultural crop protection industry while continuing to progress its research and development pipeline.

"This was a critical milestone and validation for the AgriMetis team," said Steven Tuttle, President and CEO of AgriMetis. "We are excited to transition into active business development to provide new innovative technology to the global agricultural chemical channel partners," Tuttle added.